Blood-based DNA methylation marker model for short-term and long-term lung cancer risk prediction - Top-Institutions - MDSpire

Blood-based DNA methylation marker model for short-term and long-term lung cancer risk prediction

  • By

  • Megha Bhardwaj

  • Yi-Qian Sun

  • Clara Frick

  • Ben Schöttker

  • Oluf Dimitri Røe

  • Bernd Holleczek

  • Xiao-Mei Mai

  • Hermann Brenner

  • June 6, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung
    Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung

    Saarbrücken, Saarland

    Key Differentiators

    • Oncology

  • #2

    HUNT Study (Trøndelag Health Study)
    HUNT Study (Trøndelag Health Study)

    Levanger, Trøndelag

    Key Differentiators

    • Oncology

  • #3

    Heidelberg University
    Heidelberg University

    Heidelberg, Baden-Württemberg

    Key Differentiators

    • Oncology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Oncology

  • #5

    HUNT-biobank
    HUNT-biobank

    Levanger, Trøndelag

    Key Differentiators

    • Oncology

Original Source(s)

Blood-based DNA methylation marker model for short-term and long-term lung cancer risk prediction

  • by Megha Bhardwaj, Yi-Qian Sun, Clara Frick, Ben Schöttker, Oluf Dimitri Røe, Bernd Holleczek, Xiao-Mei Mai, Hermann Brenner

  • June 6, 2026

Related Content

The evolving role of regulatory T cells in pulmonary diseases: immunomodulatory mechanisms and translational directions revealed by bibliometric analysis

Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare

Predicting response to immunochemotherapy in EGFR-mutant lung adenocarcinoma after third-generation TKI resistance using CT radiomics-based habitat imaging